| Members |
targetComponentId |
| Anastomosis of pancreas |
Anastomosis of pancreatic duct |
| Anastomosis of stomach to duodenum |
Anastomosis of stomach |
| Anatomic pathology procedure or service (procedure) |
Anatomic pathology procedure |
| Anatomical concepts |
Physical anatomical entity |
| Anatomical concepts (navigational concept) |
Physical anatomical entity |
| Anchovy - dietary (substance) |
Anchovy (substance) |
| Anderson D'Alonzo fracture type |
Fracture configurations |
| Anderson D'Alonzo type II fracture |
Anderson and D'Alonso type II fracture |
| Anderson D'Alonzo type III fracture |
Anderson and D'Alonso type III fracture |
| Androblastoma |
Androblastoma of uncertain behavior (morphologic abnormality) |
| Androstanedione |
Androstenedione (substance) |
| Androstenolone |
Dehydroepiandrosterone |
| Anemia of chronic disorder, NOS (disorder) |
anémie |
| Anemia unspecified |
anémie |
| Anesthetic gas (product) |
forme pharmaceutique gazeuse (forme pharmaceutique de base) |
| Angina decubitus NOS |
angor de décubitus |
| Angina self management plan |
Angina self management plan |
| Angioblastic meningioma |
Hemangioblastic meningioma |
| Angiocentric T-cell lymphoma |
Extranodal NK/T-cell lymphoma, nasal type |
| Angiocentric T-cell lymphoma (disorder) |
Extranodal NK/T-cell lymphoma, nasal type |
| Angiocentric T-cell lymphoma |
NK/T-cell lymphoma, nasal and nasal-type |
| Angioendotheliomatosis (disorder) |
Intravascular large B-cell lymphoma (disorder) |
| Angioendotheliomatosis |
Intravascular large B-cell lymphoma (disorder) |
| Angiofibroma |
Angiofibroma (morphologic abnormality) |
| Angioimmunoblastic lymphadenopathy with dysproteinemia |
lymphome T angioimmunoblastique |
| Angioplasty - action (qualifier value) |
Dilation - action |
| Angiotensin-converting-enzyme inhibitor allergy |
Non-allergic hypersensitivity to angiotensin-converting enzyme inhibitor |
| Angle-closure glaucoma - borderline |
Angle closure glaucoma suspect (disorder) |
| Anhydrohydroxy progesterone preparation |
Product containing ethisterone (medicinal product) |
| Anidulafungin 100mg powder for injection solution vial (product) |
Product containing only anidulafungin (medicinal product) |
| Animal ear washing |
Irrigation of ear |
| Anion (substance) |
Electrolyte anion (substance) |
| Anisocytosis |
Anisocytosis, red cells (finding) |
| Ankle brachial pressure index management plan |
Ankle brachial pressure index management plan (record artifact) |
| Ankle somatic dysfunction (finding) |
Somatic dysfunction of ankle region (finding) |
| Ankylosing vertebral hyperostosis (disorder) |
hyperostose vertébrale engainante |
| Annual |
annuel |
| Annuloplasty - action (qualifier value) |
Reconstruction - action |
| anomalous sentence repetition test - Weeks |
Anomalous sentences repetition test |
| Anosmic aphasia (finding) |
Anomic aphasia |
| Anser caerulescens |
Chen caerulescens (organism) |
| Anser caerulescens caerulescens |
Chen caerulescens caerulescens (organism) |
| Antabuse overdose |
Disulfiram overdose (disorder) |
| Antabuse poisoning |
Disulfiram poisoning (disorder) |
| Antazoline sulfate+xylometazoline hydrochloride (product) |
Product containing antazoline and xylometazoline (medicinal product) |
| Antecubital arm fasciocutaneous flap |
Fasciocutaneous flap |
| Antecubital arm flap |
Flap (substance) |
| Antenatal Anti-D prophylaxis refused (finding) |
Administration of human anti-D immunoglobulin declined |
| Antenatal blood group screening NOS |
Antenatal blood group screening categorized by action status (navigational concept) |
| Antenatal blood group screening NOS |
Antenatal blood group screening categorized by action status (navigational concept) |
| Antenatal chorionic villus sampling refused (finding) |
Sampling of chorionic villus declined |
| Antenatal hepatitis B blood screening test refused (finding) |
Antenatal screening for viral hepatitis type B declined |
| Antenatal HIV blood screening test refused |
Antenatal screening for human immunodeficiency virus declined (situation) |
| Antenatal scan unable to confirm pregnancy |
Antenatal scan unable to confirm pregnancy (finding) |
| Antenatal thalassemia blood screening test refused |
Antenatal thalassemia screening declined (situation) |
| Antenatal ultrasound confirms ectopic pregnancy |
Antenatal ultrasound confirms ectopic pregnancy (finding) |
| Antenatal ultrasound confirms intrauterine pregnancy |
Antenatal ultrasound confirms intrauterine pregnancy (finding) |
| Antepartum hemorrhage due to disseminated intravascular coagulation (disorder) |
Antepartum hemorrhage with disseminated intravascular coagulation (disorder) |
| Anterior cervical cord injury, without bony injury, C1-4 |
Anterior cervical spinal cord injury at C1-C4 level without spinal bone injury |
| Anterior cervical cord injury, without bony injury, C5-7 |
lésion antérieure de la moelle épinière cervicale, sans lésion osseuse vertébrale C5-7 |
| Anterior cervical flap |
Flap (substance) |
| Anterior chest flap |
Flap (substance) |
| Anterior thigh flap |
Flap (substance) |
| Anterior tibial fasciocutaneous flap |
Anterior tibial artery fasciocutaneous flap (substance) |
| Anterior tibial flap |
Anterior tibial artery flap (substance) |
| Antheor temporary caval filter |
Temporary vena cava filter |
| Anthralin 0.2% cream |
Product containing only dithranol in cutaneous dose form (medicinal product form) |
| Anthralin 0.2% cutaneous cream |
Product containing only dithranol in cutaneous dose form (medicinal product form) |
| Anthralin 0.4% cream |
Product containing only dithranol in cutaneous dose form (medicinal product form) |
| Anthralin 0.4% cutaneous cream |
Product containing only dithranol in cutaneous dose form (medicinal product form) |
| Anthraquinone dye |
Anthraquinone |
| Anti-D (Rh) immunoglobulin adverse reaction |
Human anti-D immunoglobulin adverse reaction (disorder) |
| Anti-D globulin NOS |
Administration of human anti-D immunoglobulin (procedure) |
| Anti-D globulin NOS |
Administration of human anti-D immunoglobulin (procedure) |
| Anti-D globulin given |
Human anti-D immunoglobulin administered (situation) |
| Anti-D globulin needed |
Administration of human anti-D immunoglobulin needed (situation) |
| Anti-D immunoglobulin given |
Human anti-D immunoglobulin administered (situation) |
| Anti-endomysium antibody |
Endomysial antibody (substance) |
| Anti-gliadin antibody |
Gliadin antibody (substance) |
| Antianaemic agent (substance) |
Medicinal product acting as antianemic agent (product) |
| Antibiotic |
médicament antibactérien |
| Antibiotic antituberculosis agent (substance) |
Antituberculosis agent |
| Antibiotic antituberculosis drug adverse reaction |
Antituberculous drug adverse reaction |
| Antibody by type |
Antibody |
| Anticardiolipin antibody (substance) |
Cardiolipin antibody |
| Anticoagulant therapy (procedure) |
Administration of anticoagulant |
| Antidiabetic agent preparation |
préparation antidiabétique |
| Antiepileptics (substance) |
Medicinal product acting as anticonvulsant agent (product) |
| Antigen to antibody in Kell blood group system |
Antibody to antigen in Kell blood group system (substance) |
| Antigout therapeutic role |
Uricosuric therapeutic role |
| Antihemophilic factor agent 1000 iu powder for conventional release solution for injection vial (product) |
Antihemophilic factor agent only product |
| Antihemophilic factor agent 1000 iu powder for injection solution 5mL vial + diluent (product) |
Antihemophilic factor agent only product |
| Antihemophilic factor agent 1500 iu powder for conventional release solution for injection vial |
Antihemophilic factor agent only product |
| Antihemophilic factor agent 1500 iu powder for injection solution 5mL vial + diluent (product) |
Antihemophilic factor agent only product |
| Antihemophilic factor agent 500 iu powder for conventional release solution for injection vial |
Antihemophilic factor agent only product |
| Antihemophilic factor agent 500 iu powder for injection solution 5mL vial + diluent (product) |
Antihemophilic factor agent only product |
| Antimongolism syndrome |
Deletion of part of autosome |
| Antineoplastic or immunosuppressive (substance) |
Medicinal product acting as antineoplastic agent (product) |
| Antiphlogistic agent (product) |
agent anti-inflammatoire |
| Antiplatelet therapeutic role (role) |
Therapeutic role (role) |
| Antipyrine + benzocaine + glycerin 54mg/14mg/1cc solution (product) |
Product containing only benzocaine and phenazone (medicinal product) |
FHIR